“Rising Preference for Targeted Therapies and Novel Drug Delivery Mechanisms”
- A significant and evolving trend in the global opioid induced constipation (OIC) drugs market is the growing shift toward targeted pharmacological therapies such as peripherally acting mu-opioid receptor antagonists (PAMORAs) and the adoption of novel drug delivery formats that enhance patient compliance and treatment outcomes. These advances are reshaping the landscape of constipation management in opioid-treated patients
- For instance, Movantik (naloxegol) and Relistor (methylnaltrexone bromide) are leading PAMORAs that offer targeted relief of OIC without impacting the central analgesic effect of opioids. They are increasingly prescribed due to their well-tolerated profiles and effectiveness in both cancer and non-cancer pain patients
- Drug development efforts are also focusing on extended-release oral formulations and subcutaneous injectables that provide flexible administration routes based on patient needs and settings. For instance, Relistor is available in both oral and injectable forms, catering to diverse patient profiles
- In addition, combination approaches, such as opioid analgesics co-formulated with constipation-reducing agents, are under investigation to minimize gastrointestinal side effects without compromising pain relief
- These trends align with growing physician and patient awareness of OIC as a distinct and manageable condition, encouraging early diagnosis and proactive treatment planning. The emphasis on patient-centric solutions, particularly in palliative and long-term care settings, is expected to continue driving innovation and market growth
